Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity

Morten B. Krag, Søren Nielsen, Zengkui Guo, Steen B. Pedersen, Ole Schmitz, Jens S. Christiansen, Jens O L Jørgensen

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Context: Peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists such as thiazolidinediones (TZDs) improve insulin sensitivity in type 2 diabetes mellitus (T2DM) through effects on fat metabolism whereas GH stimulates lipolysis and induces insulin resistance. Objective: To evaluate the impact of TZDs on fat metabolism and insulin sensitivity in subjects exposed to stable GH levels. Design: A randomized, placebo-controlled, double-blind parallel-group study including 20 GH-deficient patients on continued GH replacement therapy. The patients were studied before and after 12 weeks. Intervention: Patients received either pioglitazone 30 mg (N = 10) or placebo (N = 10) once daily for 12 weeks. Results: Adiponectin levels almost doubled during pioglitazone treatment (P = 0.0001). Pioglitazone significantly decreased basal free fatty acid (FFA) levels (P = 0.02) and lipid oxidation (P = 0.02). Basal glucose oxidation rate (P = 0.004) and insulin sensitivity (P = 0.03) improved in the patients who received pioglitazone treatment. The change in insulin-stimulated adiponectin level after pioglitazone treatment was positively correlated to the change in insulin-stimulated total glucose disposal (R = 0.69, P = 0.04). Conclusion: The impact of GH on lipolysis and insulin sensitivity can be modified by administration of TZDs.

Original languageEnglish (US)
Pages (from-to)452-461
Number of pages10
JournalClinical Endocrinology
Volume69
Issue number3
DOIs
StatePublished - Sep 2008

Fingerprint

pioglitazone
Lipolysis
PPAR gamma
Growth Hormone
Insulin Resistance
Thiazolidinediones
Adiponectin
Fats
Placebos
Insulin
Glucose
Peroxisome Proliferator-Activated Receptors
Therapeutics
Nonesterified Fatty Acids
Type 2 Diabetes Mellitus
Lipids

ASJC Scopus subject areas

  • Endocrinology

Cite this

Krag, M. B., Nielsen, S., Guo, Z., Pedersen, S. B., Schmitz, O., Christiansen, J. S., & Jørgensen, J. O. L. (2008). Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity. Clinical Endocrinology, 69(3), 452-461. https://doi.org/10.1111/j.1365-2265.2008.03231.x

Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity. / Krag, Morten B.; Nielsen, Søren; Guo, Zengkui; Pedersen, Steen B.; Schmitz, Ole; Christiansen, Jens S.; Jørgensen, Jens O L.

In: Clinical Endocrinology, Vol. 69, No. 3, 09.2008, p. 452-461.

Research output: Contribution to journalArticle

Krag, Morten B. ; Nielsen, Søren ; Guo, Zengkui ; Pedersen, Steen B. ; Schmitz, Ole ; Christiansen, Jens S. ; Jørgensen, Jens O L. / Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity. In: Clinical Endocrinology. 2008 ; Vol. 69, No. 3. pp. 452-461.
@article{c9c3c01bef564c8898a278ca62f18619,
title = "Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity",
abstract = "Context: Peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists such as thiazolidinediones (TZDs) improve insulin sensitivity in type 2 diabetes mellitus (T2DM) through effects on fat metabolism whereas GH stimulates lipolysis and induces insulin resistance. Objective: To evaluate the impact of TZDs on fat metabolism and insulin sensitivity in subjects exposed to stable GH levels. Design: A randomized, placebo-controlled, double-blind parallel-group study including 20 GH-deficient patients on continued GH replacement therapy. The patients were studied before and after 12 weeks. Intervention: Patients received either pioglitazone 30 mg (N = 10) or placebo (N = 10) once daily for 12 weeks. Results: Adiponectin levels almost doubled during pioglitazone treatment (P = 0.0001). Pioglitazone significantly decreased basal free fatty acid (FFA) levels (P = 0.02) and lipid oxidation (P = 0.02). Basal glucose oxidation rate (P = 0.004) and insulin sensitivity (P = 0.03) improved in the patients who received pioglitazone treatment. The change in insulin-stimulated adiponectin level after pioglitazone treatment was positively correlated to the change in insulin-stimulated total glucose disposal (R = 0.69, P = 0.04). Conclusion: The impact of GH on lipolysis and insulin sensitivity can be modified by administration of TZDs.",
author = "Krag, {Morten B.} and S{\o}ren Nielsen and Zengkui Guo and Pedersen, {Steen B.} and Ole Schmitz and Christiansen, {Jens S.} and J{\o}rgensen, {Jens O L}",
year = "2008",
month = "9",
doi = "10.1111/j.1365-2265.2008.03231.x",
language = "English (US)",
volume = "69",
pages = "452--461",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity

AU - Krag, Morten B.

AU - Nielsen, Søren

AU - Guo, Zengkui

AU - Pedersen, Steen B.

AU - Schmitz, Ole

AU - Christiansen, Jens S.

AU - Jørgensen, Jens O L

PY - 2008/9

Y1 - 2008/9

N2 - Context: Peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists such as thiazolidinediones (TZDs) improve insulin sensitivity in type 2 diabetes mellitus (T2DM) through effects on fat metabolism whereas GH stimulates lipolysis and induces insulin resistance. Objective: To evaluate the impact of TZDs on fat metabolism and insulin sensitivity in subjects exposed to stable GH levels. Design: A randomized, placebo-controlled, double-blind parallel-group study including 20 GH-deficient patients on continued GH replacement therapy. The patients were studied before and after 12 weeks. Intervention: Patients received either pioglitazone 30 mg (N = 10) or placebo (N = 10) once daily for 12 weeks. Results: Adiponectin levels almost doubled during pioglitazone treatment (P = 0.0001). Pioglitazone significantly decreased basal free fatty acid (FFA) levels (P = 0.02) and lipid oxidation (P = 0.02). Basal glucose oxidation rate (P = 0.004) and insulin sensitivity (P = 0.03) improved in the patients who received pioglitazone treatment. The change in insulin-stimulated adiponectin level after pioglitazone treatment was positively correlated to the change in insulin-stimulated total glucose disposal (R = 0.69, P = 0.04). Conclusion: The impact of GH on lipolysis and insulin sensitivity can be modified by administration of TZDs.

AB - Context: Peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists such as thiazolidinediones (TZDs) improve insulin sensitivity in type 2 diabetes mellitus (T2DM) through effects on fat metabolism whereas GH stimulates lipolysis and induces insulin resistance. Objective: To evaluate the impact of TZDs on fat metabolism and insulin sensitivity in subjects exposed to stable GH levels. Design: A randomized, placebo-controlled, double-blind parallel-group study including 20 GH-deficient patients on continued GH replacement therapy. The patients were studied before and after 12 weeks. Intervention: Patients received either pioglitazone 30 mg (N = 10) or placebo (N = 10) once daily for 12 weeks. Results: Adiponectin levels almost doubled during pioglitazone treatment (P = 0.0001). Pioglitazone significantly decreased basal free fatty acid (FFA) levels (P = 0.02) and lipid oxidation (P = 0.02). Basal glucose oxidation rate (P = 0.004) and insulin sensitivity (P = 0.03) improved in the patients who received pioglitazone treatment. The change in insulin-stimulated adiponectin level after pioglitazone treatment was positively correlated to the change in insulin-stimulated total glucose disposal (R = 0.69, P = 0.04). Conclusion: The impact of GH on lipolysis and insulin sensitivity can be modified by administration of TZDs.

UR - http://www.scopus.com/inward/record.url?scp=49649108052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49649108052&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2265.2008.03231.x

DO - 10.1111/j.1365-2265.2008.03231.x

M3 - Article

C2 - 18331610

AN - SCOPUS:49649108052

VL - 69

SP - 452

EP - 461

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 3

ER -